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case report
Minimal change disease 
associated with type 1 and 
type 2 diabetes mellitus
Glomerulopatia de lesões mínimas associada 
ao diabetes melito do tipo 1 e do tipo 2 
Miguel Moyses Neto1,2, Gyl Eanes Barros Silva3, Roberto S. Costa3, 
Elen A. Romão1, Osvaldo Merege Vieira Neto1,2, Marcio Dantas1
SUMMARY
A 19-year-old female with type 1 diabetes for four years, and a 73-year-old female with type 2 
diabetes for twenty years developed sudden-onset nephrotic syndrome. Examination by light 
microscopy, immunofluorescence, and electron microscopy (in one case) identified minimal 
change disease (MCD) in both cases. There was a potential causative drug (meloxicam) for the 
73-year-old patient. Both patients were treated with prednisone and responded with complete 
remission. The patient with type 1 diabetes showed complete remission without relapse, and 
the patient with type 2 diabetes had two relapses; complete remission was sustained after as-
sociated treatment with cyclophosphamide and prednisone. Both patients had two years of 
follow-up evaluation after remission. We discuss the outcomes of both patients and emphasize 
the role of kidney biopsy in diabetic patients with an atypical proteinuric clinical course, be-
cause patients with MCD clearly respond to corticotherapy alone or in conjunction with other 
immunosuppressive agents. Arq Bras Endocrinol Metab. 2012;56(5):331-5
SUMÁRIO
Uma paciente de 19 anos de idade com diabetes tipo 1 durante quatro anos e uma paciente de 
73 anos de idade com diabetes tipo 2 durante vinte anos desenvolveram quadro súbito de sín-
drome nefrótica. O exame histológico à microscopia de luz, imunofluorescência e microscopia 
eletrônica (em um caso) diagnosticou glomerulopatia de lesões mínimas (GLM) em ambos os 
casos. Na paciente de 73 anos de idade, houve uma associação com o uso de meloxicam. As 
duas pacientes foram tratadas com corticosteroides e responderam com remissão completa 
do quadro. A paciente de 19 anos com diabetes tipo 1 apresentou remissão completa sem 
recidivas, e a paciente de 73 anos com diabetes tipo 2 apresentou dois episódios de recidiva; a 
remissão completa foi conseguida após associação ao tratamento com ciclofosfamida. As duas 
pacientes foram seguidas dois anos após a remissão completa. Os casos descritos enfatizam o 
papel da biópsia renal em pacientes diabéticos com evolução atípica do aparecimento de pro-
teinúria, pois pacientes com GLM respondem bem à corticoterapia como único tratamento ou 
associado a outro agente imunossupressor. Arq Bras Endocrinol Metab. 2012;56(5):331-5
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INTRODUCTION
Proteinuria and nephrotic syndrome, which oc-cur in patients with type 1 diabetes mellitus, are 
gene rally due to diabetic nephropathy. However, ne-
phrotic proteinuria is often apparent in patients with 
insulin-dependent diabetes mellitus (type 1 diabetes), 
15-20 years after the onset of diabetes. The natural 
history of diabetic nephropathy is best described for 
type 1 diabetes, where the disease onset is more clear-
ly defined.
The natural history of diabetic nephropathy for type 
2 diabetes is not clearly defined, and a wide spectrum of 
non-diabetic glomerular diseases have been described 
in diabetic patients (1).
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The great majority of patients who are identified 
as having “minimal change disease (MCD) or lesion” 
accompanying nephrotic syndrome have a primary or 
“idiopathic” disorder. However, it is apparent that a si-
milar lesion can appear consequent to a growing num-
ber of underlying diseases. The lesion is then known 
as “secondary MCD”. Predisposing conditions include 
neoplastic diseases, toxic or allergic reactions to drugs, 
infections and autoimmune diseases (2). 
We hereby report two cases of nephrotic syndrome 
and renal biopsy-proven MCD associated with type 1 
and type 2 diabetes who went into complete remission 
after steroid therapy. 
CASE REPORTS
Case 1
A 19-year-old female with type 1 diabetes for four years 
was referred to the department because of facial and bi-
lateral limb edema that was one month in duration. She 
was being treated with insulin and Aspirin 100 mg/
day. She had no arthralgia, skin rash, impetigo, a sore 
throat or allergies. She had an uneventful pregnancy 
with a stillborn child eight months earlier. Physical exa-
mination revealed a well-developed female with a blood 
pressure of 90/70 mmHg, pulse 80 beats/min, normal 
breathing and no fever. The patient’s eyeground was 
examined; no abnormalities were found. Her weight 
at that time was 60.7 kg, and her baseline weight was 
approximately 51.0 kg. She had pitting edema on the 
legs and face. Her heart and lungs were normal, and no 
liver, spleen or lymph node enlargement were detected.
Urinalysis showed 10 white blood cells and no red 
blood cells per high-power field and granular casts. Pro-
teinuria was 5.3 g/24 h; blood urea, 33.0 mg/dL; se-
rum creatinine, 0.7 mg/dL; serum total protein, 4.2 g/
dL; albumin, 1.6 g/dL; total cholesterol, 463 mg/dL; 
blood glucose, 326 mg/dL; and hemoglobin, 13.8 g/
dL. Serology for hepatitis B and C, HIV, vasculitis and 
lupus were negative. A percutaneous renal biopsy was 
performed. The specimen included 44 glomeruli, and 
2 of these were sclerosed. The remaining glomeruli did 
not exhibit any mesangial expansion, nodule formation, 
microaneurysms, fibrin cap, or capsular drop lesion. The 
glomerular basal membrane appeared normal in thick-
ness and contour. The remaining glomeruli and the tu-
bulointerstitial compartment were unremarkable by light 
microscopy (Figure 1). In the vascular compartment, 
mild-to-moderate arteriolar hyalinosis, and mild intimal 
Figure 1. Glomeruli and tubulointerstitial area appear normal under light 
microscopic examination (Masson’s trichromic stain, original magnification: 
40x).
thickening were observed. Immunofluorescence was ne-
gative for IgG, IgM, IgA, C3, C1q, fibrinogen, kappa 
and lambda light chains. The sample for electronic mi-
croscopy contained no glomeruli. Renal histopathologic 
findings were compatible with MCD. 
Prednisone therapy using 60 mg/day was started, 
and the patient’s insulin dosage was increased. The 
patient went into complete remission with treatment. 
Prednisone dose was then gradually tapered after 8 
weeks of 60 mg/day, and discontinued after 8 mon-
ths of treatment. At that time, the laboratory findings 
showed: hemoglobin, 14.7 g/dL; leukocytes, 11,400/
mL; blood glucose, 90; total cholesterol, 209 mg/dL; 
serum albumin, 3.9 mg/dL; blood urea, 22.0 mg/dL; 
serum creatinine, 0.7 mg/dL; urinary sediment without 
abnormalities; and proteinuria, 47 mg/24 hours. The 
patient had no relapse during the two years of follow-up.
Case 2
A 73-year-old female with type 2 diabetes for twenty 
years, who was being treated with glibenclamide was 
referred to the department after complaining of an ede-
ma that was 20 days in duration. She had back pain for 
a long time and had been using meloxicam for more 
than 6 months previously. Physical examination reve-
aled blood pressure of 140/90 mmHg, pulse of 80 
beats/min, normal breathing, and no fever. She had 
pitting edema of the legs. Her eyeground was examined 
and no abnormalities were found. Her heart and lungs 
were normal, and no liver, spleen or lymph node enlar-
gement was detected. Her weight at that time was 60.0 
kg, and her baseline weight was approximately 51.0 
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kg. Proteinuria was 3.7 g/24 h; serum creatinine, 2.2 
mg/dL; blood urea, 58 mg/dL; serum albumin, 2.2 
g/dL; and Hb, 13.0 g/L. Urinalysis revealed 48,000 
red cells/mL and 10,000 leukocytes/mL. Serology for 
hepatitis B and C, vasculitis and lupus were negative. 
A percutaneous renal biopsy was performed. The 
biopsy specimen contained 21 glomeruli, all of which 
showed normal mesangial cellularity and matrix, and 
lacked immune complex deposits. The tubulointersti-
tial, vascular and glomerular compartments were unre-
markable under light microscopy. Immunofluorescence 
showed diffuse and weak granular mesangial staining 
for IgM. On electron microscopy, the glomerular ca-
pillary membrane was of normal thickness, and po-
docytes exhibited diffuse effacement of foot processes 
(Figure 2). This biopsy was compatible with MCD.
Prednisone therapy with 60 mg/day was started. In-
sulin therapy was introduced, and the patient went into 
complete remission. Prednisone dose was then gradually 
tapered after 8 weeks of 60 mg/day, and discontinued 
after 7 months of treatment. Laboratory data showed 
the following after this first treatment: Hb, 14.3 g/dL; 
blood urea, 36 mg/dL; serum creatinine, 0.8 mg/dL; 
and serum albumin, 3.6 g/dL. Five months after cessa-
tion of prednisone, she experienced a relapse. She was 
started again on prednisone treatment and went into 
complete remission. The prednisone dose was tapered 
until it reached 5 mg (5 months later). She had a second 
relapse of nephropathy. She was started again on steroid 
treatment, 90 mg daily dose of deflazacort for 8 weeks, 
and during tapering of the dose to 30 mg, 2 mg/kg 
of cyclophosphamide were administered daily to reach 
an accumulated dose of 200 mg/kg (12.0 g). She went 
into complete remission, which has been sustained for 
two years after completing treatment.
DISCUSSION
We report here two cases of a concomitant occurren-
ce of minimal change nephrotic syndrome with type 1 
and type 2 diabetes in two female adults. The patient 
with type 1 diabetes had complete and sustained re-
mission after steroid treatment, while the patient with 
type 2 diabetes had complete remission after steroid 
treatment, but had two relapses. Sustained remission 
was obtained only after steroid treatment concomitant 
with cyclophosphamide. Both kidney biopsies and cli-
nical outcomes were compatible with MCD. Both cases 
emphasize the essential role of renal biopsy in diabetic 
patients who present recent development of nephrotic 
proteinuria.
Proteinuria rarely occurs within 10 years of the 
diagnosis of type 1 diabetes mellitus, and the inciden-
ce peaks after 15-20 years. In the case described here, 
the patient had type 1 diabetes for only four years, and 
had sudden-onset nephrotic syndrome, which made us 
suspicious of a type of glomerulopathy different from 
diabetic nephropathy.
There are some reports describing MCD in pa-
tients with type 1 diabetes in the literature (21 cases 
in 11 reports), 11 with biopsy-proven MCD, and 10 
cases with diagnosis on clinical grounds (3-13). One 
report showed that the nephrotic syndrome started 
6 years before the patient developed type 1 diabetes 
(13). The authors speculate that this patient may have 
carried a genetic predisposition for the development of 
both diseases. In cases of patients with diabetes type 
1 and MCD that were described in the literature, the 
median age was 9 years (range: 3 to 61 years). Most of 
the patients were younger than 18 years, and only four 
patients were adults (more than 18 years old) (3-5,8), 
as was the patient described here. In 7 of the patients, 
the nephrotic syndrome was presented simultaneous-
ly or shortly after the diagnosis of insulin-dependent 
type 1 diabetes mellitus (median of 24 months, with a 
simultaneous range of up to 300 months). The patient 
described here had type 1 diabetes for four years before 
she developed the nephrotic syndrome.
Figure 2. Electron microscopy showing diffuse effacement of the 
epithelial cell (podocyte) foot processes (original magnification: 10,000x).
Minimal change disease with types 1 and 2 diabetes mellitus
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The coexistence of MCD and type 1 diabetes does 
not seem to be a coincidence because these two diseases 
are known to have immunological pathogeneses and, in 
some cases, are associated with other immunological di-
seases (5). The associations between MCD, neoplasms 
and drugs strongly suggest that some perturbation of 
cellular immunity is involved (2). 
As far as we know, there are only seven previously 
reported cases of MCD occurring in the setting of type 
2 diabetes mellitus (14-20), or in larger reports and re-
views (1). Data from these 7 patients are displayed in 
table 1. In larger reports, many cases were classified as 
MCD and/or focal segmental sclerosis, but the preci-
se clinical, pathological, and outcome characteristics of 
these patients were not detailed. The great majority of 
patients identified as having MCD have a primary or 
“idiopathic” disorder. Nevertheless, it is apparent that 
a similar or identical lesion can appear consequent to a 
growing number of underlying diseases, known as “se-
condary” MCD (2). There are many conditions that 
may be associated with MCD, including neoplastic dise-
ases, toxic or allergic reactions to drugs, infections and 
autoimmune disorders (2). In the case described here, 
there was an association with the use of an NSAID (me-
loxicam). In the seven cases described in the literature, 
only one case of nephrotic syndrome was suspected to 
have been induced by drugs (acarbose) (19). One pa-
tient had diffuse glomerulosclerosis with early nodular 
changes (18), three had diabetic glomerulosclerosis at a 
relatively early stage (17,19,20), and other three had no 
histopathologic changes suggestive of diabetic nephro-
pathy (14-16), as was the case of the patient described 
here. In addition to nephrotic syndrome, case 2 descri-
bed here also presented renal failure, which is common 
in elderly patients with MCD and nephrotic syndrome. 
Renal failure was resolved following treatment with ste-
roid therapy.
Similar to the majority of the previous cases (3-
15,18-20), both patients in the present study showed 
good responses to steroid therapy as the sole treatment 
in the first episode of MCD. However, in two reports 
describing MCD and type 2 diabetes (16,17), the pa-
tients responded to a single treatment with cyclosporin 
A in the first episode, which could better control their 
glycemic levels. In another report (18), the patient ex-
perienced spontaneous complete remission, and in ano-
ther case (14), a 41 year-old man developed sudden 
onset of nephrotic syndrome, and the percutaneous 
renal biopsy study showed MCD. Before immunosup-
pressive therapy, the patient presented Streptococcus sp. 
bacteremia, and acute renal failure. Afterwards, renal 
function was recovered, and complete remission of the 
nephrotic syndrome was observed. In case 2 described 
here, the patient responded to a combination of ste-
roids and cyclophosphamide, which were administered 
after the second relapse. 
This report emphasizes the need for additional stu-
dies of MCD cases associated with type 2 diabetes in 
order to determine whether there is a common event 
that induces MCD, and that renal biopsy should be 
Table 1. Minimal change disease and type 2 diabetes mellitus
Reference
Duration of 
diabetes
(years)
Age
(years) Sex Etiology
Histological alterations 
(optical microscopy) Treatment
Enriquez 
and cols. (14)
10 41 M Unknown Normal Spontaneous remission after 
Streptococcus bacteremia
Garcia Donaire and cols. 
(15)
? ? F Unknown Normal Prednisone and Prednisone + 
chlorambucil after relapse
Makibayashi and cols. 
(16)
2 67 M Unknown Mild increase in mesangial 
matrix
Prednisone
Matsuda and cols. (17) 10 65 M Unknown Normal Cyclosporin A
Pabico and cols. (18) 10 28 F Unknown Diffuse glomerulosclerosis 
and early nodular changes
Spontaneous remission
Sanada and cols. (19) 10 62 M Unknown Glomerular hypertrophy and 
mesangial expansion
Prednisolone
Stokes and cols. (20) 4 62 M Acarbose Mild increase in mesangial 
matrix
Cyclosporin A
Present case 20 73 F Meloxicam use Normal Prednisone and prednisone + 
cyclophosphamide after relapse
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considered in diabetic patients with an atypical clinical 
course (abrupt onset of nephrotic syndrome and ab-
sence of retinopathy as in this case, younger patients 
and shorter duration of diabetes) because these patients 
with MCD clearly respond to corticotherapy and/or 
other immunosuppressive therapies.
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